Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Merck KGAA pays €20mm up front for exclusive rights to Symphogen’s Sym004; rights returned

Executive Summary

Symphogen AS (therapies for autoimmune and infectious diseases and cancer) has granted Merck KGAA exclusive worldwide rights to develop and sell its lead project Sym004, an antibody mixture in Phase I/II trials for advanced KRAS wild-type metastatic colorectal cancer patients, who have previously responded to treatment with standard chemo and a marketed anti-EGFR monoclonal antibody.

Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Large Molecule
      • Antibodies
Deal Status
  • Terminated
Deal Type
  • Alliance
    • R&D and Marketing (Licensing)

Related Companies